|
See Also:
CCLE Drug Law Library
Microgram Bulletin May 2003
| other issues
| info
View
pdf version
View original on DEA's web site
Published by the Drug Enforcement Administration
Office of Forensic Sciences Washington, D.C. 20537
The U. S. Attorney
General has determined that the publication of this periodical is
necessary in the transaction of the public business required by the
Department of Justice. Information, instructions, and disclaimers
are published in the January issues.
![[Graphic Line]](file:///T|/micrograms/mg02/0202/mg98bottomline.gif)
VOL. XXXVI, NO. 5 May 2003
|
- INTELLIGENCE ALERT -
2C-I - A NEW AMPHETAMINE TYPE STIMULANT
IDENTIFIED IN DENMARK
[From the
Europol Drugs Intelligence Bulletin 2002;2:7
Unclassified; Reprinted with Permission.]
The Danish
authorities have reported a seizure, in April 2002, of a tablet with
the amphetamine type stimulant 2C-I
(2,5-dimethoxy-4-iodophenethylamine). This is the only seizure
report received by the Europol Drugs Unit on tablets with this
particular active agent. However, other sources reveal that similar
seizures have been made in Toronto, Canada and Milwaukee, USA.
 |
|
Photo 1
|
In each case
the tablet has been white with a diameter of 6 to 6.1 mm, a
thickness of 2.7 mm and displaying the "i" logo. Shown is a photo [Photo
1] of the tablet seized in Denmark:
2C-I is
chemically similar to 2C-B (regularly reported) but, according to
open source user reports, it has a slightly different effect. User
reports refer to a delayed, deep and complex effect with 15-20 mg
active substance. This may indicate a risk of overdose if sold as
ecstasy, as occurs with PMA/PMMA.
Europol Drugs
Unit kindly requests all law enforcement and forensic authorities to
report details of seizures of tablets with this logo and/or active
substance.
[Editor's
Note: To contact the Europol Drugs Unit, email to: info@europol.eu.int]
* * * * *
- INTELLIGENCE ALERT -
CANNABIS IN SUITCASE BOTTOMS/ COCAINE BRICKS
WITH STAR/WAVE
LOGOS IN THE CAYMAN ISLANDS
The Cayman Islands Forensic Laboratory (Cayman Islands Hospital,
Grand Cayman) has received a number of suitcases where cannabis
packages were concealed in false bottoms (see Photos 2
and 3). The exhibits were all seized by Her
Majesty's Customs Narcotics Enforcement Team as a result of luggage
screening at the Grand Cayman Airport. Although the technique is not
new, there was a sudden increase in this form of smuggling in 2002.
In each case, the bottom had been packed tightly with cannabis
parcels, some tailor-cut to specifically fill the spaces. In
addition, the parcels were glued in place and covered in carbon
paper. All the cases had an aromatic sweet smell (source not
identified). Analysis by microscope and GC/MS confirmed cannabis.
Total net masses of cannabis varied from approximately 8 to 25
kilograms per suitcase.
In addition, the Forensic Laboratory recently received two embossed
powder bricks, suspected cocaine. The bricks were seized by the
Royal Cayman Islands Police Drug Task Force in Grand Cayman. Each
brick weighed about 1 kilogram, and was multiply wrapped in plastic,
yellow latex, additional plastic, then grease, and finally in brown
tape. The bricks themselves had an unusual logo consisting of a
wavey line with a five-pointed star above and to the right of the
wave (see Photo 4). Analysis GC/MS, IR, and UV
confirmed 84 percent cocaine hydrochloride. These were the first
bricks of this logo type submitted to the laboratory.
 |
|
Photo 4
|
* * * * *
- INTELLIGENCE ALERT -
MDMA TABLET WITH "MEDUSA" LOGO IN REDDING,
CALIFORNIA
The Bureau of
Forensic Services Redding Regional Laboratory (Redding, California)
recently received a submission of one tablet, suspected Ecstasy. The
tablet was seized by the Redding Police Department. The submitted
tablet was round with pink and white speckles and had a woman's
profile logo - commonly known as the "Medusa" logo (see Photo 5).
Analysis by color tests and GC/MS confirmed MDMA (not quantitated).
According to the website
www.dancesafe.org, Medusa logo tablets contain (relative
percentages) both MDMA (4.8 percent) and caffeine (95.2 percent);
however, the submitted tablet was not tested for caffeine. This is
the first time that a Medusa logo tablet has been encountered by the
Redding Laboratory.
* * * * *
- INTELLIGENCE ALERT -
HOMEMADE CHOCOLATE CONTAINING
PSILOCIN/PSILOCYBIN
IN NORTH RIDGEFIELD, OHIO
The Ohio Bureau of Criminal Identification and Investigation
Laboratory (Richfield, Ohio) recently received eight pieces of
homemade chocolate containing suspected psilocybin mushrooms (total
net mass 145.76 grams; see Photo 6. Note that the four
displayed pieces in the photo were split from one of the original
eight pieces. The original pieces had shapes that suggested they
were originally molded in an ice-cube tray) The exhibits were seized
by the North Ridgeville Police Department, and were associated with
an upcoming concert in the area. Inspection of each piece revealed
the presence of vegetable matter (see photo), which was separated by
particle-picking. Analysis of a methanol extract by TLC and GC/MS
confirmed the presence of psilocin and psilocybin. This is the first
submission of this type to this laboratory; however, a second
submission containing over 150 similar homemade chocolate bars with
suspected psilocin/psilocybin mushrooms was subsequently submitted;
this latter seizure was made in Solon, Ohio and was also associated
with the referenced concert.
* * * * *
- INTELLIGENCE ALERT -
UNUSUAL OPIUM SAMPLE IN PHOENIX, ARIZONA
 |
|
Photo 7
|
The Phoenix
Police Department Laboratory Services Bureau (Phoenix, Arizona)
recently received a rather unusual submission of suspected opium.
The submission consisted of six plastic wrappers and one plastic
vial, each containing a brown brittle substance having the smell of
manure, total net mass 177 grams (for example, see Photo 7).
The exhibits were seized by the Phoenix Police Department from a
residence occupied by illegal immigrants from Honduras and Mexico. A
Marquis-based field test of the substance was negative; however, the
suspects admitted to grinding and snorting the material, so the
investigating officer requested a complete laboratory analysis. A
laboratory performed Marquis-based screen gave a faint purple color
(suggestive of an opiate). The sample was then dissolved/suspended
in 0.2 N sulfuric acid, washed with chloroform, made basic with
solid potassium carbonate, and then extracted with chloroform /
isopropanol (4:1). A second Marquis test performed on the residue
resulting from evaporation of the latter organic extract gave a
bright purple color. Analysis of the extract by GC/MS confirmed
codeine, morphine, papaverine, and noscapine (not quantitated). The
adulterants were not identified, and it is unclear why the raw
material gave a false negative with the Marquis, or why it had a
smell resembling manure. This was the first opium sample received in
recent history by the Phoenix Police Department Laboratory Services
Bureau.
* * * * *
- INTELLIGENCE ALERT -
OPIUM POPPIES SOLD OVER THE INTERNET FROM
CALIFORNIA
The DEA Western Laboratory (San Francisco, California) recently
received some usual submissions of suspected opium poppies,
including some that were artificially colored (see Photo 8).
The poppies were purchased over the Internet by the DEA San Jose
Regional Office (combined net mass of three purchases 6.899
kilograms). The dried poppies were being advertised as "floral
decorations". The purchases eventually led to the seizures of 3
boxes of dried poppies from a storage locker in Sacramento, and then
an additional 42 boxes of dried poppies from a warehouse in Santa
Paula (California). In total, the combined seizures equaled about
25,500 pods, with a net mass of about 120.8 kilograms. The poppy
pods were similar in shape but ranged in height from ½ to 2 inches.
The poppies were bundled in sets of 15-20 smaller poppies, or 3-10
larger poppies, either wrapped with rubber bands or contained in
plastic flower sleeves. Most of the poppies were a natural light
brown color, but (as noted above) many were dyed in different
colors, including purple, blue, orange, pink, and yellow. Analysis
by GC/FID and GC/MS confirmed morphine and codeine. Quantitation of
a typical pod indicated 1.72 milligrams of morphine, which
extrapolates to about 44 grams of morphine for the entire seizure.
This is the first opium poppy case of this size and origin to be
submitted to the Western Laboratory, and the first poppy case of any
type in several years.
* * * * *
- INTELLIGENCE ALERT -
"HANDSHAKE" LOGO TABLETS CONTAINING 1-METHAMPHETAMINE
IN SPRINGFIELD, MISSIOURI
 |
|
Photo 9
|
The DEA North Central Laboratory (Chicago, Illinois) recently
received 50 blue tablets with a "handshake" logo on one side,
suspected Ecstasy (see Photo 9). The tablets were purchased
in Springfield, Missouri by investigators from the Springfield,
Missouri Police Department and agents from the DEA St. Louis
Division Mobile Enforcement Team. The tablets were round, flat-faced
on both sides with the blank side having a slight beveled edge, 8.0
mm in diameter, and weighed 235 milligrams each. Analysis by GC
(with and without chiral derivatization with
(S)-(-)-N-trifluoroacetylprolyl chloride (TPC)), FTIR, and GC/MSD
indicated a mixture of
l-methamphetamine (16 mg/tablet calculated as the hydrochloride
salt), 3,4- methylenedioxymethamphetamine (55 mg/tablet calculated
as the hydrochloride salt),
and ketamine (16 mg/tablet calculated as the hydrochloride salt).
 |
|
Photo 10
|
The Laboratory also received an unrelated but highly similar
submission of 93 blue-gray "handshake" logo tablets, also round,
flat-faced on both sides with the blank side having a slight beveled
edge, 8.0 mm in diameter, and weighed 240 milligrams each, also
suspected Ecstasy (see Photo 10). In this case, the tablets
were purchased in St. Louis, Missouri by agents from the DEA St.
Louis Division. Analysis in this case, however, indicated a mixture
of d,l-methamphetamine (17 mg/tablet calculated as the hydrochloride
salt), 3,4-methylenedioxymethamphetamine (55 mg/tablet calculated as
the hydrochloride salt),
and ketamine (17 mg/tablet calculated as the hydrochloride salt) -
virtually identical except
for the enantiomeric composition of the methamphetamine.
[Editor's Notes: Although the "handshake" logo is a known source,
and mixed MDMA/ methamphetamine/ketamine "Ecstasy" tablets have also
been previously encountered, the presence of d,l-methamphetamine and
especially l-methamphetamine in such tablets are certainly unusual
findings. According to the analyst in this case, the laboratory has
encountered several subsequent submissions of similar tablets.]
* * * * *
- INTELLIGENCE ALERT -
VERY LARGE PCP LABORATORY SEIZED IN BALTIMORE,
MARYLAND
The DEA Mid-Atlantic Laboratory (Largo, Maryland) recently assisted
the DEA Baltimore District Office, Bureau of Alcohol, Tobacco, and
Firearms (ATF), Maryland Department of the Environment, and the
Baltimore City Police Department in taking down a very large-scale
phencyclidine (PCP) manufacturing operation. Two locations were
involved; the first was a residence in northwest Baltimore where the
actual synthesis was being performed, while the second was a
business in Jessup, Maryland which was being used to purchase large
amounts (i.e., 55-gallon drums) of listed chemicals such as
piperidine, phenylmagnesium bromide, and cyanide (Jessup is located
about 15 miles south of Baltimore). The large quantities received by
the business were subdivided into smaller units for use by the
laboratory. The business, which was involved in manufacturing
industrial cleaners, tried to justify the purchase of these
chemicals by claiming that they were better ingredients for their
cleaning products.
At the Baltimore residence, agents, officers, and chemists found
forty-two 5-gallon buckets in the basement (see
Photo 11). Thirty-nine contained various liquids,
subsequently identified as benzene, phenylmagnesium bromide, and
cyclohexanone; however, three contained a white powder that was
presumptively identified as a cyanide salt (probably sodium or
potassium, not formally determined). Other chemicals included three
50-pound bags of sodium metabisulfite, seven 800-mL bottles of
phenylmagnesium bromide in ether, and thirteen empty 500-mL bottles
that had contained piperidine (see Photo 12).
A total of approximately 4.5 gallons of finished liquid PCP was
identified, distributed between nine different beverage containers.
In total, the identified chemicals indicated the use of the Maddox
method of PCP synthesis. This combines the cyclohexanone, piperidine,
cyanide salt, and sodium metabisulfite to form
1-piperidinocyclohexanecarbonitrile (PCC). The phenylmagnesium
bromide solution is added to the PCC to form PCP. One bucket
contained an ongoing reaction.
Analysis was conducted using GC, GC/MS and FTIR. The total amount of
phencyclidine was calculated at 3.8 kilograms. The production
capacity range was quite impressive. Based on the least abundant
precursor, piperidine, the theoretical yield was calculated as 16
kilograms, whereas based on the most abundant precursor,
cyclohexanone, the theoretical yield was 355.9 kilograms. Assuming a
modest concentration of 75 mg/mL, this operation therefore could
have produced anywhere from 56 to 1255 gallons of liquid PCP. Of
note, a Baltimore City Police Officer present at the site commented
that the largest previous seizure of liquid PCP in Baltimore was
only one gallon.
 |
 |
|
Photo 11
|
Photo 12
|
* * * * *
- INTELLIGENCE ALERT -
5-METHOXY-ALPHA-METHYLTRYPTAMINE
(5-MEO-AMT) APPEARING
IN SUGAR CUBES AND LSD-STYLE BLOTTER PAPERS
The DEA Special Testing and Research Laboratory (Dulles, Virginia)
has recently received multiple reports of sugar cubes and LSD-style
blotter papers containing 5-methoxy-alpha-methyltryptamine
(5-MeO-AMT). Drug abuse literature (unconfirmed) suggests that this
tryptamine is relatively potent. The mass spectra of 5-MeO-AMT is
provided below; complete analytical data will follow in a later
issue of Microgram Bulletin or Microgram Journal.

* * * * *
- SCHEDULING UPDATE-
ALPHA-METHYLTRYPTAMINE (AMT) AND
5-METHOXY-N, N-DIISOPROPYL-TRYPTAMINE
(5-MeO-DIPT, "FOXY") ARE EMERGENCY SCHEDULED
EVENT: Temporary placement of alpha-methyltryptamine
(AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) into
Schedule I through emergency scheduling provision of the CSA
DATE OF EVENT: April 4, 2003
REPORTING ELEMENT: DEA Office of Diversion (OD)
WHEN REPORTED: April 8, 2003
SUMMARY: This is to provide you with an update on the
Emergency scheduling of alpha-methyl-tryptamine (AMT) and
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) into Schedule I of
the CSA. AMT and 5-MeO-DIPT are tryptamine derivatives and share
chemical and pharmacological similarities with the Schedule I
tryptamine hallucinogens, alpha-ethyltryptamine (AET) and N,N-dimethyltryptamine
(DMT), respectively. AMT and 5-MeO-DIPT are stimulant/hallucinogens
abused for their abilities to induce hallucinatory states. AMT can
produce nervous tension, irritability, restlessness, inability to
sleep, blurry vision, pupillary dilatation, hallucinations and
dextroamphetamine-like mood elevating effects. 5-MeO-DIPT can
produce talkativeness, disinhibition, pupillary dilatation, nausea,
jaw clenching, muscle tension and overt hallucinations with both
auditory and visual distortions. There are no legitimate medical or
scientific uses of AMT and 5-MeO-DIPT. The safety of human
consumption of these substances has not been determined. Since 1999,
law enforcement officials in several states have encountered AMT.
The abuse by teens and young adults of AMT and 5-MeO-DIPT is an
emerging problem. There have been reports of abuse of AMT and
5-MeO-DIPT at clubs and raves. Many tryptamine-based substances
including AMT and 5-MeO-DIPT are illicitly available from United
States and foreign chemical companies and from individuals through
the Internet. There is also evidence suggesting the attempted
clandestine production of AMT and 5-MeO-DIPT.
In response to this apparent growing problem and to avoid an
imminent harm, a Final Notice temporarily placing AMT and 5-MeO-DIPT
into Schedule I of the Controlled Substances Act (CSA) pursuant to
the temporary scheduling provisions of the CSA was published in the
Federal Register on April 4, 2003 (68 FR 16427). This adds to three
other substances, namely N-benzylpiperazine (BZP),
1-(3-trifluoromethyl-phenyl) piperazine (TFMPP), and
2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), that were
temporarily scheduled into Schedule I through a Final notice
published in Federal Register on September 20, 2002 (67 FR 59161 and
67 FR 59163).
The Drug and Chemical Evaluation Section within the Office of
Diversion Control is collecting information to support the final
scheduling actions for these substances.
* * * * *
Selected Intelligence Brief
Information Bulletin: GHB Analogs. GBL, BD, GHV,
and GVL.
National Drug Intelligence Center
319 Washington St., 5th Floor
Johnstown, PA 15901
[Unclassified; Reprinted With Permission (Minus
Four Case Vignettes)]

Introduction
Because the criminal penalties associated with GHB (gamma-hydroxybutyrate)
have been made more stringent and law enforcement pressure has
rendered GHB more difficult to obtain, the distribution and abuse of
GHB analogs have become an increasing concern. GHB analogs, which
include GBL, BD, GHV, and GVL, are drugs that possess chemical
structures that closely resemble GHB. The ingestion of any of these
analogs produces physiological effects similar to the effects
associated with GHB abuse--relaxation, mild euphoria, and
drowsiness. Abusers who emerge from a deep sleep or coma caused by
GHB analogs may become easily agitated and extremely combative. GHB
analogs are of particular concern because they contribute to
increasing numbers of auto accidents, sexual assaults, and deaths.
While federal law prohibits the sale of analogs for human
consumption, GHB analogs are available legally as industrial
solvents used to produce polyurethane, pesticides, elastic fibers,
pharmaceuticals, coatings on metal or plastic, and other products.
These analogs also are sold illicitly as supplements for
bodybuilding, fat loss, reversal of baldness, improved eyesight, and
to combat aging, depression, drug addiction, and insomnia. GBL and
BD are sold as "fish tank cleaner," "ink stain remover," "ink
cartridge cleaner," and "nail enamel remover" for approximately $100
per bottle--much more expensive than comparable products. Law
enforcement's efforts to identify the abuse of GHB analogs are
hampered by the fact that routine toxicological screens do not
detect the presence of these analogs. In addition, distributors
continually develop new analogs to avoid law enforcement detection.
Analogs
GHB analogs often are abused in place of GHB or are used to produce
GHB. Common GHB analogs include GBL, BD, GHV, and GVL. (See Table
1.) Both GBL and BD metabolize into GHB upon ingestion. GBL is the
most common precursor used in the production of GHB. GVL is abused
in place of GHB because it metabolizes into GHV, which produces
physiological effects similar to GHB.
Table 1. GHB Analogs
|
Analog
|
Chemical
Name/Alternative Name
|
Precursor for
Production of
|
Metabolizes Into
|
|
GBL
|
gamma-butyrolactone
furonone di-hydro
dihydrofuranone
|
GHB
|
GHB
|
|
BD
|
1,
4-butanediol
tetramethylene glycol
sucol-B
butylene glycol
|
GBL
|
GHB
|
|
GHV
|
gamma-hydroxyvalerate
methyl-GHB
|
O
|
*
|
|
GVL
|
gamma-valerolactone
4-pentanolide
|
GHV
|
GHV
|
* GHV is not used as a precursor and is not metabolized into another
drug.
Abuse
GHB analogs are distributed as liquids and consumed orally. When
ingested, these analogs produce effects such as relaxation, mild
euphoria, and drowsiness. Such effects are similar to those
associated with GHB abuse and may resemble the results of alcohol
intoxication. GHB analogs also may increase libido, suggestibility,
passivity, and cause amnesia--traits that make users vulnerable to
sexual assault and other criminal acts. Users awakening or emerging
from coma may exhibit extreme combativeness, a condition which is
also observed among those in withdrawal from addiction to GHB and
its analogs. GHB analogs are known to produce side effects such as
topical irritation to the skin and eyes, nausea, vomiting,
incontinence, loss of consciousness, seizures, liver damage, kidney
failure, respiratory depression, and even death. GHB analogs are
physically addictive, causing addicts to experience severe
withdrawal symptoms if they miss a dose or attempt to stop using the
drug.
Some GHB analog abusers begin consuming dietary supplements
believing the claims made by manufacturers, and then find themselves
addicted to the product. GHB analogs typically are abused in place
of GHB by users who want to experience the effects associated with
GHB and who find the analogs more widely available or easily
obtained. Often users are unaware that they are consuming an analog
and mistakenly believe that the substance they are ingesting is GHB.
Many users mix the analogs with flavored beverages to mitigate their
salty flavor and unappealing odor. Some users, however, simply
ingest the drugs straight or mixed with water. It is often difficult
or impossible to detect the presence of GBL, BD, GHV, or GVL when
they are mixed with other liquids because these analogs are all
clear and colorless. A quick test that indicates the possible
presence of GHB analogs or GHB in a clear liquid involves shaking
the liquid. If it becomes cloudy, GHB analogs or GHB may be present.
Because GHB analogs either are metabolized into GHB by the human
body or produce similar physiological effects when ingested,
healthcare providers often are unable to distinguish between the
abuse of GHB and GHB analogs. Thus, the rising abuse of GHB,
evidenced by the increase in Drug Abuse Warning Network (DAWN)
emergency department mentions, reflects increased GHB analog use as
well. (See Table 2.)
Table 2. Emergency Department Mentions for GHB
and GBL
in 22 Major U.S. Cities, 1994 - 2000.
|
Year
|
Total
|
|
1994
|
56
|
|
1995
|
145
|
|
1996
|
638
|
|
1997
|
762
|
|
1998
|
1,282
|
|
1999
|
3,178
|
|
2000
|
4,969
|
Source:
Substance Abuse and Mental Health Services
Administration, Drug Abuse Warning Network.
Distribution
GHB analogs
are readily available, and various methods are used to distribute
these drugs. Because of legislation (see Legislation section), GHB
analogs are legally available only in products not intended for
human consumption. Abusers and distributors may obtain commercial
products such as chemical solvents legally and then illegally
consume or distribute them. Illegal distribution of GHB analogs
often occurs at raves, concerts, nightclubs, health clubs, gyms, and
on college campuses. At these venues GHB analogs usually are sold
for $10 to $20 per capful (approximately 1 teaspoonful). When
distributors sell these drugs, they may fail to specify which analog
they are selling, or they may misrepresent the analog as GHB.
GHB analogs
also are distributed at disreputable stores that sell health food
and nutritional supplements. The analogs also may be marketed on the
Internet and then shipped to purchasers via package delivery
services. Typically, analogs are marketed as dietary supplements,
sleep aids, and cleaning products. They are packaged in bottles
containing 4 to 20 ounces and sold for $40 to $100 each. The
products that are distributed as dietary supplements usually contain
GVL as the active ingredient, while the cleaning supplies usually
contain GBL or BD. The concentration of the analog varies;
therefore, the size of a dose may range from one-half teaspoon to
one-half ounce, and the number of doses per bottle may range from 24
to 48.
Individuals
who illegally produce GHB analogs for human consumption often list
alternative chemical names to disguise the ingredients. Most users
recognize the analog by the brand name or through advertisements
that tout the product as a replacement for a similar product that
has been removed from the market. Products that contained BD or GBL
such as RenewTrient II, Serenity, Inner-G, Soma Solution, and Blue
Nitro are no longer sold, primarily because of law enforcement
pressure, but comparable products with similar brand names are
available.
GHB analogs
often are sold with disclaimers that they are not for human
consumption; however, many of the products have labels implying that
the product may be ingested. One product marketed as an industrial
solvent has a label that states "Warning! Accidental ingestion of
[product] will produce GHB in your body. If you ingest some by
mistake, don't take alcohol or any other drug!" Another product
label states "Warning: Accidental ingestion may
cause...euphoria...increases tactile sensitivity...". Many of the
products are marketed as "Great Household Bargains" (GHB) in order
to increase their exposure to individuals seeking GHB analogs.
In addition
to the distribution methods discussed previously, supplies, kits,
and recipes for producing GHB using the GHB analog GBL are marketed
and sold on the Internet.
Tests for GHB Analogs
Seized GHB
analogs frequently are not identified because detection of such
analogs requires specific field and laboratory testing. Three
different color tests--cobalt nitrate, Marquis reagent, and Mandelin
reagent--are useful for detecting the presence of GHB analogs.
(Contact forensic laboratories to obtain specific instructions
regarding utilizing these test kits.) Both the Marquis reagent and
the Mandelin reagent tests are available commercially.
Routine
toxicological screens do not detect GHB or GHB analogs; thus, law
enforcement officers and medical personnel must order specific blood
and urine tests when they suspect GHB analog abuse. The most common
urine tests screen only for the "NIDA-5," five of the most commonly
abused categories of drugs--amphetamines (amphetamines,
methamphetamine), cocaine (powdered cocaine, crack), cannabinoids
(marijuana, hash), opiates (heroin, opium, codeine, morphine), and
phencyclidine (PCP). GHB in the blood or urine can result from the
ingestion of GHB, GBL, or BD. To yield a reliable result, tests for
GHB and GHB analogs must be performed not long after ingestion.
Urine tests for GHB and GHB analogs must be performed within 12
hours after ingestion, and blood tests must be performed within 5
hours.
Federal,
state, and local forensic laboratories may not routinely test for
GHB in blood or urine. For example, the Florida Department of Law
Enforcement (FDLE) began testing for GHB in urine on December 1,
2000, but tests are performed only if the suspect exhibits symptoms
indicating the presence of GHB. FDLE does not have the resources to
conduct blood tests; if blood tests are needed, the samples to be
tested must be sent to outside laboratories--some of which are
located in other states.
Because GHB
analogs produce effects similar to GHB, driving under the influence
of the analogs is just as dangerous as driving under the influence
of GHB. As a result, some agencies have adopted aggressive
strategies for identifying drivers who may have consumed GHB. The
Pinellas-Pasco Medical Examiner's Office in Florida conducts GHB
tests on drivers who are suspected of driving under the influence
(DUI). In 2000 GHB was detected in approximately 8 percent of the
suspected DUI cases that the office examined.
Legislation
On February
18, 2000, the "Hillory J. Farias and Samantha Reid Date-Rape
Prohibition Act of 1999" (Public Law 106-172) was signed into law,
legislating GHB as a Schedule I controlled substance. GBL was also
regulated under this law as a List I controlled chemical. Illicit
use of GHB analogs may now be prosecuted as Schedule I substances
under 21 U.S. Code § 813.
GHB analogs
are treated as controlled substances under Federal law only if
intended for human consumption. According to 21 U.S.C. § 813, "a
controlled substance analog(ue) shall, to the extent intended for
human consumption, be treated, for the purposes of any Federal law
as a controlled substance in Schedule I." Thus, authorities can
prosecute drug offenses involving GHB analogs in the same manner as
offenses involving GHB. (See 21 U.S.C. § 802(32) for the definition
of a controlled substance analog(ue).)
Outlook
Deterring the
distribution and abuse of GHB analogs poses unique challenges. Some
analogs have legitimate purposes and are legally available.
Distributors of illicit GHB analogs will continue to develop new
products to disguise their activities, and illicit producers will
continue to develop new GHB analogs for the same reasons. Web sites
advertising these products will continue to be deceptive and
ever-changing. Distributors will develop new disguises for GHB
analogs in addition to marketing them as cleaning fluids and dietary
supplements. Sharing current information and associated trends
relating to GHB analogs among medical personnel, law enforcement
officers, and laboratory personnel is essential to stemming the
distribution and abuse of these analogs.
* * * * *
SELECTED REFERENCES
[Note: Selected references are a compilation of recent publications
of presumed interest to forensic chemists. Unless otherwise stated,
all listed citations are published in English. If available, the
email address for the primary author is provided as the contact
information. Listed mailing address information (which is sometimes
cryptic or incomplete) exactly duplicates that listed by the
abstracting services.]
1. Piette
V, Parmentier F. Analysis of illicit amphetamine seizures by
capillary zone electrophoresis. J Chromatogr A 2002;979:345.
[Editor's Notes: Presents a CZE methodology for analysis of
typical drugs found in Ecstasy tablets. Contact: Laboratory of
Drug Analysis, Scientific Institute of Public Health - Louis
Pasteur, Rue Juliette Wytsman 14, B-1050 Brussels, Belgium.]
2.
Briellmann TA, Dussy FE, Bovens MG. Forensic analysis of heroin
and cocaine seizures. Chimia 2002;56:74. [Editor's Notes:
Presents a survey and overview of seizures in Switzerland (date
range not specified in abstract). Contact: Institute of Forensic
Medicine, Pestalozzistrasse 22, CH-4004 Basel, Switzerland.]
3. Tishmack
PA, Bugay DE, Byrn SR. Solid-state nuclear magnetic resonance
spectroscopy - pharmaceutical applications. Journal of
Pharmaceutical Sciences 2003;92(3):441. [Editor's Notes: A
mini-review of the title topic, focusing on solid pharmaceutical
drug formulations. Contact:
dbugay@ssci-inc.com]
4. Kelly
SA, Glynn PM, Madden SJ, Grayson DH. Impurities in a morphine
sulfate drug product identified as 5-(hydroxymethyl)-2-fufural,
10-hydroxymorphine and 10-oxomorphine. Journal of
Pharmaceutical Sciences 2003;92(3):485. [Editor's Notes: The
referenced impurities were isolated by semi-prep HPLC and
identified via MS and NMR. The presence of sugars in the drug
formulation was implicated in the formation of the impurities.
Contact:
sean_kelly2@merck.com]
5. DeBoer
D, Goemans WPJ, Ghezavat VR, vanOoijen RD, Maes RAA. Seizure of
illicitly produced para-fluorofentanyl: Quantitative analysis of
the content of capsules and tablets. Journal of Pharmaceutical
and Biomedical Analysis 2003;31(3):557. [Editor's Notes: Presents
a GC/MS methodology for the title analysis; HPLC/UV was also used
to quantify caffeine being used as an adulterant. The samples
derived from an illicit laboratory in the Netherlands. Contact: D
deBoer, Inst Nacl Desporto, Lab Anal Dopagem & Bioquim, Av Prof,
P-1600190 Lisbon, Portugal.]
6. Khalil
S, Kelzieh A. New polyvinyl chloride membrane electrode without
inner reference solution for the determination of methadone.
Journal of Pharmaceutical and Biomedical Analysis 2003;31(3):601.
[Editor's Notes: Presents a direct potentiometric method for
analyzing methadone in pharmaceutical preparations. Contact: S
Khalil, Techers Coll Riyadh, Dept Chem, POB 4341, Riyadh 11491,
Saudi Arabia.]
7. Sun GX,
Wang Y, Sun YQ. The quantitative determinations of glycyrrhizic
acid, glycyrrhetinic acid, morphine, and sodium benzoate in
compound liquorice tablets by HPCE. Journal of Liquid
Chromatography & Related Technologies 2003;26(1):43. [Editor's
Notes: Presents a CZE/UV method to perform the title analysis.
Contact: Sun GX, Shenyang Pharmaceut Univ, 103 Wenhua Rd, Shenhe
Dist, Shenyang 110016, Peoples R China.]
8. Jarikote
DV, Siddiqui SA, Rajagopal R, Daniel T, Lahoti RJ, Srinivasan KV.
Room temperature ionic liquid promoted synthesis of
1,5-benzodiazepine derivatives under ambient conditions.
Tetrahedron Letters 2003;44(9):1835. [Editor's Notes: Presents a
novel synthetic approach to the title compounds. Contact:
Srinivasan KV, Natl Chem Lab, Div Organ Chem Technol, Dr Homi
Bhabha Rd, Pune 411008, Maharashtra, India.]
9. Qi ML,
Wang P, Zhou L, Gu JL, Fu RN. Simultaneous determination of
acetaminophen, detromethorphen [sic] and pseudoephedrine
hydrochloride in a new drug formulation for cold treatment by HPLC.
Chromatographia 2003;57(3-4):139. [Editor's Notes: Presents a
validated method for the referenced analysis, which is completed
in less than 10 minutes per run. Contact: Qi ML, Beijing Inst
Technol, Sch Chem Engn & Mat Sci, Dept Chem, Beijing 100081,
Peoples R. China.]
10. Gelfman
DE, Teder O. Method and apparatus for detection of illegal
substances in commerce. U.S. Pat. Appl. Publ. US 2003 33,851 (Cl.
73-19.01; G01N7/00), 20 Feb 2003, Appl. 927,895, 10 Aug 2001.
[Editor's Notes: Presents a device for collecting and analyzing
particulates of drugs, explosives, and toxic materials. The
analytical basis is not specified. Contact: No address information
was provided.]
Additional References of Possible Interest:
1.
Robertson MD, Marinetti LJ. Carisoprodol - Effects on Human
Performance and Behavior. Forensic Science Review
2003;15(1):1. [Editor's Notes: A minor review of the title
compound, focusing on impaired driving performance. Contact:
Independent Forensic Consulting, Beaumaris, Victoria, Australia.]
2. Logan BK,
Couper FJ. 3,4-Methylenedioxymethamphetamine - Effects on human
performance and behavior. Forensic Science Review
2003;15(1):11. [Editor's Notes: A minor review of the title
compound, focusing on impaired driving performance. Contact:
Forensic Laboratory Services Bureau, Washington State Patrol,
Seattle, Washington (zip code not provided in the abstract).]
3. Stout
PR, Farrell LJ. Opioids - Effects on Human Performance and
Behavior. Forensic Science Review 2003;15(1):29. [Editor's
Notes: A minor review of the title compound, focusing on impaired
driving performance. Contact: Navy Drug Screening Laboratory,
Naval Air Station Jacksonville, Jacksonville, Florida (zip code
not provided in the abstract).]
4. Mozayani
A. Phencyclidine - Effects on human performance and behavior.
Forensic Science Review 2003;15(1):61. [Editor's Notes: A general
review of PCP, including information on its detection,
identification, and analysis. Contact: Harris County Medical
Examiner's Office, Houston, Texas (zip code not provided in
abstract).]
5. Vickers
AK, Rood D. Advances in column technology. Gas
Chromatographic Techniques and Applications 2001;(No Volume #):91.
[Editor's Notes: Presents a review of advances in GC column
technology. Contact: Agilent Technologies / J&W Scientific,
Folsom, CA 95630.]
6. Przybyl
AK, FlippenAnderson JL, Jacobsen AE, Rice KC. Practical and
high-yield syntheses of dihydromorphine from tetrahydrothebaine
and efficient syntheses of (8S)-8-bromomorphide. Journal of
Organic Chemistry 2003;68(5):2010. [Editor's Notes:
Dihydromorphine is prepared in 92% yield. Contact: Rice KC, NIDDKD,
Med Chem Lab, NIH, Bldg 8, Room B1-22, 8 Ctr Dr, MSC 0815,
Bethesda, MD 20892.]
7. Zagnoni
PG, Albano C. Psychostimulants and Epilepsy. Epilepsia
2002;43(Supp. 2):28. [Editor's Notes: A minor review of the
correlation between seizures and illicit drug use. Contact: Unita
Operativa di Neurologia, ASL 15 Cuneo, Italy.]
8. Da Matta
Chasin AA, De Carvalho DG, Pedrozo MDFM, De Souza MC, Sanson LN.
Occurrence of lidocaine in samples of crack/cocaine seizures in
the metropolitan region of Sao Paulo and in biological fluids
analysed in the Forensic Toxicology Laboratory, Medical Legal
Institute (IML) in Sao Paulo from January to June of 2000.
Bull TIAFT 2003;33(1):7. [Editor's Notes: Includes analysis data
from seized drugs; however, primary focus is analysis of
biological fluids. Contact: IML, Medical Legal Institute, Sao
Paulo, Brazil.]
9. Song YR,
Wang DF, Hu YP, Chen XX, Jiao YG, Hou DY. Direct separation and
quantitative determination of clenbuterol enantiomers by high
performance liquid chromatography using an amide type chiral
stationary phase. Journal of Pharmaceutical and Biomedical
Analysis 2003;31(2):311. [Editor's Notes: Focus is on profiling
clenbuterol enantiomers in human serum. Contact: Song YR, Beijing
Normal Univ, Dept Chem, Beijing 100875, Peoples R China.]
10. Myers
S. Forensic science. Nature 2003;421(6925):872. [Editor's
Notes: Presents a minor overview of the development of forensic
DNA laboratories; includes some general comments of interest on
the "real-life value" of forensic laboratories. Contact: No
address information was provided.]
11.
Petersen JR, Ohorodudu AO, Mohammad A, Payne DA. Capillary
Electrophoresis and its application in the clinical laboratory.
Clinica Chimica Acta 2003;330(1-2):1. [Editor's Notes: Presents an
overview of CE use and potential in clinical laboratories,
comparing and contrasting to traditional electrophoretic and HPLC
methods. Contact: Department of Pathology, University of Texas
Medical Branch, Galveston, TX (zip code not provided).]
12.
Matsumoto T, Sano T, Matsuoka T, Aoki M, Maeno Y, Nagao M. Case
Report: Simultaneous determination of carisoprodol and
acetaminophen in an attempted suicide by liquid chromatography -
mass spectrometry with positive electrospray ionization.
Journal of Analytical Toxicology 2003;27(2):118. [Editor's Notes:
Presents the analysis of carisoprodol, meprobamate, and
acetaminophen by LC/MS. The focus is biological testing of urine
and plasma. Contact: Aichi Prefectural Police Hdqrs., Criminal
Investigation Laboratory, 1-1 Sannomaru 2-chome, Naka-ku, Nagoya
460-8502, Japan.]
13. Li J.
Determination of cocaine and its metabolites. Zhongguo
Yaowu Yilaixing Zazhi 2002;11(2):90. [Editor's Notes: A review on
the detection of cocaine and its metabolites. This article is
written in Chinese. Contact: Normal College of Vocational
Technology, Peking United University, Beijing 100011, Peop. Rep.
China.]
14. Cordani
P. Self defense test strip package for drug testing in food and
drinks. U.S. Pat. Appl. Publ. US 2003 26,731 (Cl.
422-58;G01N31/22), 6 Feb 2003, Appl. 923,507, 6 Aug 2001.
[Editor's Notes: Discusses a test-strip in the shape of a drinking
straw or stirrer for discreetly determining the presence of
(undeclared) drugs (presumably date-rape drugs). Contact: No
address information was provided.]
15. Brennan
J, Dillon P, OKennedy R. Production, purification and
characterisation of genetically derived scFv and bifunctional
antibody fragments capable of detecting illicit drug residues.
Journal of Chromatography B - Analytical Technologies in the
Biomedical and Life Sciences 2003;786(1-2):327. [Editor's Notes:
The referenced antibodies were created to detect morphine, and
were applied to saliva. Contact: J Brennan, Dublin City Univ, Sch
Biotechnol, Appl Biochem Grp, Dublin 9, Ireland.]
16.
Mancinelli R, Guiucci MS. Procedural and interpretative
problems in the determination of drugs of abuse. Annali
dell'Istituto Superiore di Sanita 2002;38(3):305. [Editor's Notes:
Presents an overview of the state of the art of analytical
toxicology. This article is written in Italian. Contact:
Laboratorio di Biochimica Clinica, Istituto Superiore di Sanita,
Rome, Italy.]
* * * * *
EMPLOYMENT OPPORTUNITIES
1. Johnson
County Sheriff's Office Criminalistics Laboratory (2 Positions)
(Third and Final Posting)
Position
1: DNA Technical Leader/ Forensic Chemist
Location: Mission, Kansas (Kansas City metropolitan area)
Salary: $50,564.80 to $72,280.00 per year
Application Deadline: Open Until Filled
Duties:
This position will serve as the laboratory's DNA Technical
Leader and section coordinator. The major duties of this position
include overseeing the technical operations of the Biology Section
to ensure compliance with the American Society of Crime Laboratory
Directors/Laboratory Accreditation Board Standards (ASCLD/LAB) as
well as the Quality Assurance Standards for Forensic DNA Testing
Laboratories standards. In addition, this position will have some
casework responsibility; including evaluating the nature, origin and
significance of physical evidence both in the laboratory and at
crime scenes; performing physical, chemical, biochemical and genetic
analysis of biological material associated with evidence using DNA
analysis methods; maintaining laboratory records, preparing written
technical reports of analysis, and providing effective expert
testimony in courts of law. This position will oversee the training
of laboratory examiners and the evaluation and implementation of new
scientific techniques for the DNA section of the laboratory. The
successful applicant will also be a commissioned Deputy Sheriff.
General
Requirements: Candidates must meet the educational and
experience requirements for a DNA Technical Leader as published in
Section 5.2 of the Quality Assurance Standards for Forensic DNA
Testing Laboratories (U.S. Department of Justice, Federal Bureau of
Investigation, 07/15/98). These guidelines are available on-line at:
http://www.cstl.nist.gov/biotech/strbase/dabqas.htm Candidates
without a Master's degree must already possess a waiver of the
degree requirements as provided in section 5.2.1.1 of the above
standards. The successful candidate must also meet the minimum
qualifications of a Deputy Sheriff.
The applicant
will be required to successfully complete the Kansas Law Enforcement
Training Center curriculum. Also, the applicant will be required to
successfully complete a laboratory training program in biology and a
qualifying test before beginning independent casework
responsibilities.
----------
Position
2: Firearms and Tool Mark Examiner
Location: Mission, Kansas (Kansas City metropolitan area)
Salary: $50,564.80 to $72,280.00 per year
Application Deadline: Open Until Filled
Duties:
The major duties include examining firearms for function;
comparison with bullets and cartridge cases; serial number
restoration; GSR examination of clothing associated with firearm
cases; and tool mark examinations. Other duties may be assigned
based upon the qualifications of the successful applicant. The
successful applicant will become a commissioned Deputy Sheriff and
will be required to complete the Kansas Law Enforcement Training
Center curriculum. Also, the successful applicant will be required
to successfully complete a qualifying test before beginning
independent casework responsibilities.
General
Requirements: A minimum of three years of experience in firearm
and tool mark examination. Experience must include the completion of
a two-year, full-time training program under the direction of an
experienced firearms and tool mark examiner. In addition, the
successful candidate must have a least one-year of experience doing
independent casework examination and being qualified as an expert
witness in a court of law in the area of firearms and tool mark
examination. Experience with the National Integrated Ballistic
Information Network (NIBIN) and familiarity with the Association of
Firearms and Tool Mark Examiners' (AFTE) Guidelines and the American
Society of Crime Laboratory Directors/Laboratory Accreditation
Board's (ASCLD/LAB) Standards is desired. Applicants must also meet
the minimum qualifications of a Deputy Sheriff.
----------
Application Procedures for both Positions: Applications can be
obtained by contacting the Sheriff's Department Personnel Division
at the following address.
Johnson
County Sheriff's Department, Personnel and Training, 125 N. Cherry,
Olathe, KS 66061; Phone: (913) 791-5511 (or Toll Free at: (866)
262-3744)
Additional
Information about this position can be obtained from Director L.
Keith Kerr at the Crime Laboratory by calling: (913) 826-3209.
The Johnson
County Sheriff's Department does not discriminate on the basis of
race, color, national origin, sex, religion, age, or disabled status
in employment or the provision of programs and services.
* * * * *
SCIENTIFIC MEETINGS
1. Title:
Mid-Atlantic Association of Forensic Sciences (MAAFS) Annual
Meeting (Second and Final Posting)
Sponsoring Organization: Mid-Atlantic Association of Forensic
Sciences
Inclusive Dates: May 5 - 9, 2003
Location: Annapolis, MD (Sheraton Barcelo)
Meeting Registration Procedure, Deadline, and Costs: [See
website]
Recommended Lodging (Registration Deadline and Costs): [See
website]
Contact Individual's Name, Phone Number, and email Address:
[See website]
Website: [www.maafs.org/annualmeeting.htm]
* * * * *
2. Title:
Annual New England Seminar in Forensic Sciences (Second Posting)
Sponsoring Organization: Colby College, Special Programs
Inclusive Dates: August 10 - 14, 2003
Location: Colby College, Waterville, ME
Meeting Registration Procedure, Deadline, and Costs: [See
website]
Recommended Lodging (Registration Deadline and Costs): [See
website]
Contact Individual's Name, Phone Number, and email Address:
Jesse Davis, 207/872-3386 (FAX -3383),
summer@colby.edu
Website: [www.colby.edu/spec.prog/cme.html]
* * * * *
3. Title:
29th Annual Meeting of the Northeastern Association of Forensic
Scientists (First Bimonthly Posting)
Sponsoring Organization: Northeastern Association of Forensic
Scientists
Inclusive Dates: November 5 - 8, 2003
Location: Crowne Plaza Hotel, Pittsfield, MA
Meeting Registration Procedure, Deadline, and Costs: [Not
Provided]
Recommended Lodging (Registration Deadline and Costs): [Not
Provided]
Contact Individual's Name, Phone Number, and email Address:
Jennifer F. Limoges, 518/457-0054 (FAX 485-8502),
jlimoges@troopers.state.ny.us
Website: [Not Provided]
4. Title:
SWAFS 2003 Training Conference (First Bimonthly Posting)
Sponsoring Organization: Southwestern Association of Forensic
Scientists
Inclusive Dates: November 3 - 6, 2003
Location: Radisson Plaza Hotel, Fort Worth, TX
Meeting Registration Procedure, Deadline, and Costs: [Not
Provided]
Recommended Lodging (Registration Deadline and Costs): [see:
www.radisson.com/ftworthtx 800/333-3333]
Contact Individual's Name, Phone Number, and email Address:
Michelle O'Neal, 817/920-5700, x163,
fortworth2003@swafs.org
Website: [www.swafs.org]
* * * * * * * * * * * * * * * * * * * * * * * * *
THE DEA FY-2003 STATE AND LOCAL
FORENSIC CHEMISTS SEMINAR SCHEDULE
The remainder
of the FY - 2003 schedule for the DEA's State and Local Forensic
Chemists Seminar is as follows:
June 9 –
13, 2003
September 15 – 19, 2003
Note that the
school is open only to forensic chemists working for law enforcement
agencies, and is intended for chemists who have completed their
agency's internal training program and have also been working on the
bench for at least one year. There is no tuition charge for this
course. The course is held in Northern Virginia, near the
Washington/Dulles International Airport. For additional information,
eligibility requirements, or to enroll, see the September 2002 issue
of Microgram Bulletin, or call 703 668-3337.
* * * * * * * * * * * * * * * * * * * * * * * * *
| Technical and Administrative
Reviews |
by: Michael J. Phelan
DEA Special Testing and
Research Laboratory |
One of the
essential elements of a digital evidence laboratory quality
assurance program is a thorough review of the draft reports of
examination. The review process should utilize a check and balance
philosophy to ensure that the final reports are both technically
sound and administratively consistent with laboratory policies.
Digital evidence examination reports are often quite complex
because the findings are usually both numerous and varied. Reports
typically include a mixture of statements of fact and examiner
opinions.
DEA's
review process operates on two different levels. A Group
Supervisor or senior examiner performs the first level (technical)
review, while the Laboratory Director usually conducts the second
level (administrative) review. The technical review covers seven
reporting areas, as follows:
Report
Identification
First, the
descriptive identification information is checked. Case numbers,
exhibit numbers, laboratory numbers, file title, and report
distribution are compared to the original documentation and
verified. Case Examination File
Second, the case examination folder is reviewed to ensure
completion of all appropriate internal laboratory forms. DEA's
Digital Evidence Laboratory makes extensive use of "check the box"
or "fill in the blank" forms to ensure that the evidence is
adequately characterized for both identification and examination
purposes. A typical examination first requires a form describing
all objects to be examined. A second form that describes the
computer, its peripherals, and pertinent hardware or firmware
information (including CMOS clock setting and hard drive geometry
information) is checked. A third form that focuses on the hard
drive(s), detailing the number of hard drives, storage capacity,
partition numbers, and file structures is reviewed. A fourth and
final form that details all of the parameter settings used by the
examiner to acquire a copy of the original evidence is also
checked.
Chain of
Custody
The third
reporting area covers the chain of custody, which is reviewed by
comparing the submitted evidentiary paperwork to the report
narrative. Appropriate signature completion blocks are reviewed on
the incoming chain of custody document. Computer make, model, and
serial number documentation, along with hard drive make, model,
and serial number are verified. Other incoming evidence
documentation, such as United States Postal Service registered
mail or Federal Express shipping numbers, and counts of objects
submitted for examination, are also reviewed. Most of this
information is recorded on the internal laboratory forms as well
as in the report of examination narrative. All of this information
must be accurately recorded.
This
information is very important, because a typical chain of custody
suppression motion will most likely focus on any discrepancies in
this area. [This is because it is the least technical and
therefore one of the best understood aspects of evidence handling
and analysis by defense attorneys.]
Report
Organization
Fourth, the
report is reviewed for general content. At DEA, this consists of
an inspection of the organizational format and standard findings
paragraph. DEA's organizational review consists of a simple check
of layout format to insure that all findings paragraphs are
numbered in accordance with DEA laboratory policy, and also that
the report synopsis is concise and to the point. The standard
findings paragraphs can be extensive, and will reflect individual
laboratory examination protocols. DEA's standard findings
paragraphs usually consist of the following: 1) A statement
documenting the duplication of the original evidence to make a
working copy, and the recording of an archive copy onto a tape; 2)
A statement documenting a computer virus scan (and the results);
3) An enumeration of the key word search terms; 4) A listing of
all file names, with associated date and time stamp information;
and 5) The documenting of the sealing of the archive backup tape
in a numbered DEA heat seal evidence envelope.
Findings
Assessed
Fifth, the
case specific findings detailed in the body of the report of
examination are reviewed. Typically, findings are stored on a CD
in a format that is easily accessed by the Case Agent. The report
of examination should clearly identify where the finding of
interest (such as a file or file fragment) was found on the
original evidence (directory and file name, or hard drive sector).
Additionally, the location of the file copy of the finding on the
report's accompanying CD needs to be documented. Occasionally,
findings are printed onto paper, and initialed and dated by the
examiner. The findings should be organized into simple paragraphs
to simplify reader understanding and focus. A one-sentence summary
of each finding is included in the report, to indicate to the
reader what kind of information has been recovered and included on
the CD. This synopsizing process facilitates the rapid review of
the material by the Case Agent. For example, financial information
belonging to the XYZ business, or e-mail belonging to
badguy@domain.com was found
in the "My Documents" folder, and was copied to the "My Documents"
folder on the findings CD. Findings must also be documented in the
examination notes. A technical review of the findings should
assess the wording used by the examiner. Technical jargon such as
free space, slack area, and carve, if needed, should be kept to a
minimum and explained in layman's terms when possible.
CD Check
Sixth, a CD
containing the findings must be checked to ensure that the
findings (files or file fragments) referenced in the report of
examination are all present and can all be opened. It is important
that every file cited in the report of examination be precisely
named as stated in the report, and located exactly where the
report states it to be. Also, the CD containing the findings must
be appropriately labeled, initialed, and dated by the examiner.
The CD is the equivalent of a paper attachment.
Methodology Review
Seventh,
the examination checklist needs to be reviewed. Have the broad
examination milestones such as file browsing, keyword searching
and file execution tasks been completed? Findings and conclusions
must be consistent with the methodology and software tools
utilized. Both the base examination software (such as Encase,
Ilook, or Forensic Tool Kit) and any specialty examination
software (such as e-mail reader software or data carving software)
need to be documented.
Administrative Review
A second
individual, usually the Laboratory Director, conducts the
administrative review. The administrative review spot checks the
previously described technical review areas, and also looks at the
overall scope of examination to determine if the level of effort
was commensurate with the type and seriousness of the case.
Administrative reviews also critically assess the language used in
the report, to ensure that all assertions and conclusions are
supportable and can be easily understood by non-technical
personnel.
This
two-tier review process is an excellent method of ensuring both
quality control and uniformity of effort within the laboratory.
Reviews are time consuming, averaging 30-45 minutes per report.
A third
tier can be added to the process by establishing a quarterly peer
review committee to further check the work of the technical and
administrative reviewers. The use of peer review committee is a
well recognized quality assurance technique in most forensic
laboratories, and is highly recommended.
Typical
Problems Detected
The typical
types of problems that are detected in the review process fall
into two categories. New examiners often have problems with their
writing styles, i.e.; their reports are too technical and/or
contain unnecessary, overstated, or unsupported statements. More
senior examiner personnel occasionally become lackadaisical or
complacent, and the examination note quality or details in their
report writing become deficient. The findings CD may not be
thoroughly checked, or files may not be accessible or properly
labeled. DEA has found the dual review process invaluable in
producing a reliable product on a consistent basis.
Questions
or comments:
E-mail: mphelan@erols.com
See Also
CCLE Entheogen and Drug Policy Project
CCLE Drug Law Library |